4,901 trials
Healthy Subjects
Primary: Part 1: Area Under The Plasma Concentration-Time Curve From Time 0 to 12 Hours (AUC [0-12]) of Maraviroc — 3441; 2954; 2181; 2947 nanogram*hour per milliliter (ng*hr/mL)…
Pre-diabetes
Primary: Change From Baseline in Circulating Urinary Concentrations of Intact Epicatechin and Epi Metabolites — 105.8; 132.7; 162.3; 291.3 nM*hr — p=0.05
Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available
Primary: Number of Subjects With Any Dose Limiting Toxicity (DLT) — 1; 3; 2 subjects
Hyperparathyroidism, Secondary
Primary: Number of Participants With Adverse Events — 2; 0; 1; 2 participants
Breast Cancer
Primary: Percentage of Participants Demonstrating a Decrease in the Growth Factor Signature (GFS) — 28.6; 17.6 Percentage of participants
Secondary Hyperparathyroidism in Patients With ESRD on Hemodialysis
Primary: Cumulative Excretion of Radioactivity — 35.29; 24.26; 0.75; 2.40 Percentage of administered dose
Dengue
Primary: Systemic and Local Reactogenicity Rates for Ungraded Symptoms — 0; 1; 0; 2 Participants
Malignancy · Metastasis
Primary: Number of Participants With Adverse Events (AEs) — 3; 7; 6; 1 participants
Healthy
Primary: Area Under the Concentration-time Curve of Nintedanib in Plasma Over the Time Interval From 0 to the Last Quantifiable Concentration (AUC0-tz) — 195; 193 nanogram…
Adrenal Insufficiency
Primary: Maximum Serum Concentration (Cmax) — 940.012; 896.489; 1563.479 nmol/L
Healthy
Primary: Area Under the Concentration-time Curve of the Telmisartan in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point (AUC0-tz) — 2850; 2790…
Healthy
Primary: Maximum Measured Concentration (Cmax) of the Analytes in Plasma — 697; 726; 3.62; 3.57 ng/mL
Healthy Adults
Primary: Number of Participants With Treatment- Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) — 6; 4; 6; 5 Participant
Epilepsy, Molecular Mechanisms of Pharmalogical Action, Protective Agents
Primary: Cholesterol 24S-Hydroxylase (CH24H) Brain Enzyme Occupancy as a Function of TAK-935 Plasma Concentration at 45 Minutes Post-TAK-935 Dose — NA; 98; NA percentage of…
Cancer
Primary: Number of Participants With Adverse Events — 3; 3; 5; 3 Participants